

**Brovana (arformoterol)  
Perforomist (formoterol)  
Effective 01/01/2024**

<b>Plan</b>	<input type="checkbox"/> MassHealth UPPL <input checked="" type="checkbox"/> Commercial/Exchange	<b>Program Type</b>	<input checked="" type="checkbox"/> Prior Authorization <input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
<b>Benefit</b>	<input checked="" type="checkbox"/> Pharmacy Benefit <input type="checkbox"/> Medical Benefit		
<b>Specialty Limitations</b>	N/A		
<b>Contact Information</b>	<b>Medical and Specialty Medications</b>		
	All Plans	Phone: 877-519-1908	Fax: 855-540-3693
	<b>Non-Specialty Medications</b>		
	All Plans	Phone: 800-711-4555	Fax: 844-403-1029
<b>Exceptions</b>	N/A		

#### Overview

Brovana and formoterol are within the class of sympathomimetics and are long-acting beta agonists approved for treatment of chronic obstructive pulmonary disease.

#### Coverage Guidelines

Authorization may be granted for members new to the plan who are currently receiving treatment with Brovana or formoterol, excluding when the product is obtained as samples or via manufacturer's patient assistance programs

#### OR

Approval of Brovana and/or formoterol will be granted if the member meets all following criteria and documentation has been submitted:

1. The member has a diagnosis of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema **AND**
2. Clinical rationale why the member is unable to use a non-nebulized long-acting beta-agonist **and has no claims for inhalers within the past 30 days.**

#### Limitations

1. Initial approvals and reauthorizations will be granted for 12 months
2. The following quantity limits apply:

Brovana	#60 vials per 30 days
---------	-----------------------

#### References

1. Brovana (arformoterol) [prescribing information]. Marlborough, MA: Sunovion Pharmaceuticals Inc; May 2019
2. Perforomist (formoterol) [prescribing information]. Morgantown, WV: Mylan Specialty L.P; May 2019.

3. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Bethesda, MD: Global Initiative for Chronic Obstructive Lung Disease; 2015.  
[http://www.goldcopd.org/uploads/users/files/GOLD\\_Report\\_2015\\_Apr2.pdf](http://www.goldcopd.org/uploads/users/files/GOLD_Report_2015_Apr2.pdf). Accessed August 7,
4. Rodrigo GJ, Nannini LJ, Rodriguez-Roisin R. Safety of long-acting beta-agonists in stable COPD: a systematic review. *Chest*. 2008;133(5):1079-1087
5. Hanania NA, Donohue JF, Nelson H, et al. The safety and efficacy of arformoterol and formoterol in COPD. *COPD*. 2010;7(1):17-31. [[PubMed 20214460](#)]

### Review History

11/05/07 – Implemented

09/24/07 – Reviewed

09/22/08 – Updated

09/21/09 – Reviewed

09/27/10 – Updated

09/19/11 – Reviewed

09/24/12 – Reviewed

09/23/13 – Reviewed

09/22/14 – Updated

09/21/15 – Reviewed

09/19/16 – Reviewed

09/18/17 – Reviewed

09/18/19 – Added disclaimer on other inhaler use

07/21/2021 – reviewed July P&T; Perferomist came out generic; criteria updated to include formoterol. Started and stabilized statement updated to say “members new to the plan”. Effective 10/01/2021.

10/11/2023 – Reviewed and updated at Oct P&T; Added approval duration for initial authorizations and reauthorizations. Effective 1/1/24

